Market Overview

Buying The Dip In Nevro Pays Off For Investors After Court Ruling

Buying The Dip In Nevro Pays Off For Investors After Court Ruling

Prior to a big bounce Wednesday morning, Nevro Corp (NYSE: NVRO) stock was down nearly 50 percent in the past month. Much of the drop came Tuesday following what the market perceived as bad news tied to the company’s patent dispute with Boston Scientific Corporation (NYSE: BSX).

Yet Nevro shares are up 35 percent Wednesday, and analysts said those who bought the dip made the right call.  

The Analysts 

JPMorgan analyst Robbie Marcus reiterated an Overweight rating on Nevro with a $77 price target. 

Canaccord Genuity analyst Jason Mills reiterated a Buy rating with an $80 price target.

JPMorgan's Take

A U.S. District Court ruled Tuesday that four of the seven patents involved in the dispute are invalid, and Boston Scientific was granted non-infringement on all remaining claims.

JPMorgan's Marcus said the market seems to have initially misinterpreted the news as negative for Nevro, but his interpretation is the exact opposite.

“Our interpretation is that while Boston doesn’t infringe Nevro’s three remaining patents with its current trials and U.S. commercialized tonic stimulation devices ... the ruling does imply that any attempt to actually commercialize a high-frequency device in the US remains an infringement of Nevro’s remaining patents ‘102 and ‘472,” the analyst said in a note.

Canaccord’s Take

Canaccord's Mills said in a Wednesday note that investors shouldn’t be too quick to throw the baby out with the bathwater.

“In fact, NVRO lawyers’ interpretation of the summary judgment — per our conversation with management AMC — is that it did indeed render ‘invalid as indefinite’ Nevro’s ‘system’ patents, but they believe the ruling actually upheld its ‘method’ patents,” the analyst said.

The method patents are key to the technology application and should limit competition, Mills said. 

Following Tuesday’s sell-off, Nevro’s stock was trading at a 60-percent discount to the rest of the small-cap med-tech group based on estimated 2018 enterprise value-per-sales, according to Canaccord. 

Where The Stock Goes From Here

Dip buyers who got ahead of the trade Wednesday are enjoying huge gains, but analysts forecast even more potential upside ahead for Nevro stock.

Nevro shares were up 34.06 percent at $59.24 at the time of publication Wednesday.

Related Links:

Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile

Leerink: Translate Bio's Cystic Fibrosis Candidate Could Generate $1.8B

Photo courtesy of Nevro. 

Latest Ratings for NVRO

Jan 2020MaintainsSell
Jan 2020Initiates Coverage OnBuy
Jan 2020DowngradesOutperformPerform

View More Analyst Ratings for NVRO
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Price Target Reiteration Legal Analyst Ratings General Best of Benzinga


Related Articles (BSX + NVRO)

View Comments and Join the Discussion!

Latest Ratings

RPAYCantor FitzgeraldMaintains18.0
CMSCredit SuisseDowngrades
PBCTStephens & Co.Maintains15.5
TTECCowen & Co.Initiates Coverage On50.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at